Nadciśnienie tętnicze indukowane terapią sunitinibem Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2011
Słowa kluczowe:
jatrogenne nadciśnienie tętnicze, sunitinib, terapia antyangiogenna, kardiotoksyczność, leczenie hipotensyjne, czynnik predykcyjny
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze jest częstą chorobą współistniejącą u chorych na raka nerki oraz częstym powikłaniem terapii sunitinibem. Blokowanie szlaku zależnego od VEGF prowadzi do dysfunkcji śródbłonka, zmniejszenia wytwarzania tlenku azotu oraz zmniejszenia gęstości naczyń mikrokrążenia. Klinicznie skutkuje to wzrostem obwodowego oporu naczyniowego, a w konsekwencji wzrostem ciśnienia tętniczego krwi. Rozpoznanie jatrogennego nadciśnienia tętniczego powinno być zgodne z obowiązującymi rekomendacjami European Society of Hypertension oraz Polskiego Towarzystwa Nadciśnienia Tętniczego. Przydatne są samodzielne pomiary domowe, a w niektórych sytuacjach 24-godzinny ambulatoryjny pomiar ciśnienia. Wczesne rozpoznanie jatrogennego nadciśnienia tętniczego daje szansę zastosowania optymalnego leczenia hipotensyjnego i zapobieżenia późniejszej kardiotoksyczności. Przy wyborze leków hipotensyjnych należy pamiętać o chorobach współistniejących, leki te nie powinny wchodzić w interakcje z sunitinibem. Nadciśnienie powodowane przez sunitinib jest korzystnym czynnikiem predykcyjnym terapii przeciwnowotworowej, dlatego odstawienie sunitinibu z powodu nadciśnienia powinno być rzadkością.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Szmit S, Filipiak KJ, Zaborowska M, Gębara-Puchniarz A, Szczylik C. Nadciśnienie tętnicze indukowane terapią sunitinibem. OncoReview [Internet]. 30 wrzesień 2011 [cytowane 23 listopad 2024];1(3(3):202-16. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/257
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Launay-Vacher V., Deray G.: Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009 Jan; 20(1): 81-2.
2. Sica D.A.: Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 2006; 24: 1329-31.
3. Motzer R.J., Rini B.I., Bukowski R.M. et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
4. Demetri G.D., van Oosterom A.T., Garrett C.R. et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
5. Motzer R.J., Hutson T.E., Tomczak P. et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
6. Chu T.F., Rupnick M.A., Kerkela R. et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
7. Zhu X., Stergiopoulos K., Wu S.: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009; 48(1): 9-17.
8. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J.: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-1096.
9. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events version 3.0 (CTCAE). Bethesda: National Cancer Institute 2003. Online: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
10. Folkow B.: ‘Structural factor’ in primary and secondary hypertension. Hypertension 1990; 16: 89-101.
11. Mourad J.J., des Guetz G., Debbabi H., Levy B.I.: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 2008; 19: 927-934.
12. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W., Edwards H.V. et al.: Impaired microvascular dilation and capillary rarefaction in young adults with a predisposition to high blood pressure. J. Clin. Invest. 1997; 99: 1873-1189.
13. Sane D.C., Anton L., Brosnihan K.P.: Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
14. Eremina V., Jefferson J.A., Kowalewska J. et al.: VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008; 358: 1129-1136.
15. Alavi A., Hood J.D., Frausto R., Stupack D.G., Cheresh D.A.: Role of RAF in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-96.
16. Govindarajan R., Adusumilli J., Baxter D.L., El-Khoueiry A., Harik S.I.: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J. Clin. Oncol. 2006; 24: e48.
17. Kapiteijn E., Brand A., Kroep J., Gelderblom H.: Sunitinid induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol. 2007; 18: 1745-1747.
18. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A. et al.: Neutralizations of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003; 278: 12605-12608.
19. Gibbons G.H., Dzau V.J.: The emerging concept of vascular remodeling. N. Engl. J. Med. 1994; 330: 1431-1438.
20. Bhoola K.D., Figueroa C.D., Worthy K.: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992; 44: 1-80.
21. Minshall R.D., Erdös E.G., Vogel S.M.: Angiotensin I-converting enzyme inhibitors potentiate bradykinin’s inotropic effects independently of blocking its inactivation. Am. J. Cardiol. 1997; 80: 132A-136A.
22. Vallance P., Collier J., Moncada S.: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
23. Gardiner S.M., Compton A.M., Bennett T., Palmer R.M., Moncada S.: Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492.
24. Horowitz J.R., Rivard A., van der Zee R., Hariawala M., Sheriff D.D., Esakof D.D. et al.: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2793-2800.
25. Hood J.D., Meininger C.J., Ziche M., Granger H.J.: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998; 274: H1054-H1058.
26. Gordon M.S., Cunningham D.: Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: S25-S33.
27. Porta C., Szczylik C.: Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat. Rev. 2009 May; 35(3): 297-307.
28. Mancia G., De Backer G., Dominiczak A. et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J. Hypertens. 2007 Sep; 25(9): 1751-62.
29. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura J.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie tętnicze 2011; 15(2): 55-82.
30. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G. et al.: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol. 2008; 53: 917-930.
31. Maitland M.L., Bakris G.L., Black H.R., Chen H.X., Durand J.B., Elliott W.J., Ivy S.P., Leier C.V., Lindenfeld J., Liu G., Remick S.C., Steingart R., Tang W.H.; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 2010 May 5; 102(9): 596-604.
32. Azizi M., Chedid A., Oudard S.: Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 2008; 358(1): 95-97.
33. Maitland M.L., Kasza K.E., Karrison T.G. et al.: Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 2009; 15(19): 6250-6257.
34. Bamias A., Lainakis G., Manios E., Koroboki E., Gyftaki R., Zakopoulos N., Dimopoulos M.A.: Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J. Chemother. 2009 Jun; 21(3): 347-50.
35. Lainakis G., Bamias A., Manios E. et al.: 24-hour arterial blood pressure monitoring in patients with renal cell carcinoma treated with sunitinib results in control of hypertension without dose reduction in the majority of patients. Ann. Oncol. 2008; 18(suppl; abstr 603P): 195.
36. Houk B.E., Bello C.L., Michaelson M.D., Bukowski R.M., Redman B.G., Hudes G.R. et al.: Exposure-response of sunitinib in metastatic renal carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J. Clin. Oncol. 2007; 25(suppl 18): 241s.
37. Rini B.I.: Biomarkers: hypertension following anti-angiogenesis therapy. Clin. Adv. Hematol. Oncol. 2010; 8(6): 415-6.
38. Rini B.I., Cohen D.P., Lu D., Chen I., Hariharan S., Gore M.E.: Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. ASCO GU meeting 2010; Abstr 312.
39. Ravaud A., Sire M.: Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and secondline treatment of metastatic renal cell cancer. Ann. Oncol. 2009; 20: 966-967.
40. Rixe O., Billemont B., Izzedine H.: Hypertension as a predictive factor of sunitinib activity. Ann. Oncol. 2007; 18: 1117.
41. Bono P., Rautiola J., Utriainen T., Joensuu H.: Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011; 50(4): 569-73.
42. Rini B.I., Cohen D.P., Lu D.R., Chen I., Hariharan S., Gore M.E., Figlin R.A., Baum M.S., Motzer R.J.: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2011 May 4; 103(9): 763-73.
43. Szmit S., Langiewicz P., Żołnierek J., Nurzyński P., Zaborowska M., Filipiak K.J., Opolski G., Szczylik C.: Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines. Kidney Blood Press Res. 2011 Aug 18; 35(1): 18-25.
44. Ghoreschi K., Laurence A., O’Shea J.J.: Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 2009; 10: 356-360.
45. Kerkela R., Woulfe K.C., Durand J.B. et al.: Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2009; 2: 15-25.
46. Hsieh P.C., MacGillvray C., Gannon J., Cruz F.U., Lee R.T.: Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114: 637-44.
47. Khakoo A.Y.: Regulation of hypertrophic responses by PDGFRβ. American Heart Association, Basic Cardiovascular Sciences annual meeting. Lake Las Vegas, NV; 2009 July 21st.
48. Wang C.H., Anderson N., Li S.H. et al.: Stem cell factor deficiency is vasculoprotective: Unraveling a new therapeutic potential of imatinib mesylate. Circ. Res. 2006; 99: 617-625.
49. Steinberg S.F.: PI3King the L-type calcium channel activation mechanism. Circ. Res. 2001; 89: 641-644.
50. Di Lorenzo G., Autorino R., Bruni G. et al.: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol. 2009; 20(9): 1535-1542.
51. Bamias A., Lainakis G., Manios E., Koroboki E., Karadimou A., Zakopoulos N., Dimopoulos M.A.: Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J. Clin. Oncol. 2009 May 20; 27(15): 2567-9.
52. Khakoo A.Y., Kassiotis C.M., Tannir N., Plana J.C., Halushka M., Bickford C. et al.: Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-8.
53. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S.: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 2008; 19: 1613-8.
54. Szmit S., Nurzyński P., Szaluś N., Opolski G., Szczylik C.: Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2009; 48(6): 921-5.
55. Schmidinger M., Zielinski C.C., Vogl U.M. et al.: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008; 26: 5204-5212.
56. Jain M., Townsend R.R.: Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr. Hypertens. Rep. 2007; 9(4): 320-328.
57. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G.: Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Cancer Urol. Assoc. J. 2007; 1(Suppl): S41-S54.
58. Lacy C.F., Armstrong L.L., Goldman M.P.: Cytochrome P-450 enzymes and drug metabolism. W: Drug information handbook. Lacy C.F., Armstrong L.L., Goldman M.P (red.). Wyd. 12. Hudson, Ohio: Lexi-Comp; 2004: 1619-1631.
59. Szmit S., Filipiak K.J.: Nadciśnienie jako powikłanie współczesnej farmakoterapii onkologicznej. W: Nadciśnienie tętnicze – co nowego? Kasprzak J.D., Nowicki M. (red.). Cornetis (w druku).
60. Dougall H.T., McLay J.: A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996; 15: 91-106.
2. Sica D.A.: Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 2006; 24: 1329-31.
3. Motzer R.J., Rini B.I., Bukowski R.M. et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
4. Demetri G.D., van Oosterom A.T., Garrett C.R. et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
5. Motzer R.J., Hutson T.E., Tomczak P. et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
6. Chu T.F., Rupnick M.A., Kerkela R. et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
7. Zhu X., Stergiopoulos K., Wu S.: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009; 48(1): 9-17.
8. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J.: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-1096.
9. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events version 3.0 (CTCAE). Bethesda: National Cancer Institute 2003. Online: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
10. Folkow B.: ‘Structural factor’ in primary and secondary hypertension. Hypertension 1990; 16: 89-101.
11. Mourad J.J., des Guetz G., Debbabi H., Levy B.I.: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 2008; 19: 927-934.
12. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W., Edwards H.V. et al.: Impaired microvascular dilation and capillary rarefaction in young adults with a predisposition to high blood pressure. J. Clin. Invest. 1997; 99: 1873-1189.
13. Sane D.C., Anton L., Brosnihan K.P.: Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
14. Eremina V., Jefferson J.A., Kowalewska J. et al.: VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008; 358: 1129-1136.
15. Alavi A., Hood J.D., Frausto R., Stupack D.G., Cheresh D.A.: Role of RAF in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-96.
16. Govindarajan R., Adusumilli J., Baxter D.L., El-Khoueiry A., Harik S.I.: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J. Clin. Oncol. 2006; 24: e48.
17. Kapiteijn E., Brand A., Kroep J., Gelderblom H.: Sunitinid induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol. 2007; 18: 1745-1747.
18. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A. et al.: Neutralizations of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003; 278: 12605-12608.
19. Gibbons G.H., Dzau V.J.: The emerging concept of vascular remodeling. N. Engl. J. Med. 1994; 330: 1431-1438.
20. Bhoola K.D., Figueroa C.D., Worthy K.: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992; 44: 1-80.
21. Minshall R.D., Erdös E.G., Vogel S.M.: Angiotensin I-converting enzyme inhibitors potentiate bradykinin’s inotropic effects independently of blocking its inactivation. Am. J. Cardiol. 1997; 80: 132A-136A.
22. Vallance P., Collier J., Moncada S.: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
23. Gardiner S.M., Compton A.M., Bennett T., Palmer R.M., Moncada S.: Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492.
24. Horowitz J.R., Rivard A., van der Zee R., Hariawala M., Sheriff D.D., Esakof D.D. et al.: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2793-2800.
25. Hood J.D., Meininger C.J., Ziche M., Granger H.J.: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998; 274: H1054-H1058.
26. Gordon M.S., Cunningham D.: Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: S25-S33.
27. Porta C., Szczylik C.: Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat. Rev. 2009 May; 35(3): 297-307.
28. Mancia G., De Backer G., Dominiczak A. et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J. Hypertens. 2007 Sep; 25(9): 1751-62.
29. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura J.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie tętnicze 2011; 15(2): 55-82.
30. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G. et al.: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol. 2008; 53: 917-930.
31. Maitland M.L., Bakris G.L., Black H.R., Chen H.X., Durand J.B., Elliott W.J., Ivy S.P., Leier C.V., Lindenfeld J., Liu G., Remick S.C., Steingart R., Tang W.H.; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 2010 May 5; 102(9): 596-604.
32. Azizi M., Chedid A., Oudard S.: Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 2008; 358(1): 95-97.
33. Maitland M.L., Kasza K.E., Karrison T.G. et al.: Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 2009; 15(19): 6250-6257.
34. Bamias A., Lainakis G., Manios E., Koroboki E., Gyftaki R., Zakopoulos N., Dimopoulos M.A.: Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J. Chemother. 2009 Jun; 21(3): 347-50.
35. Lainakis G., Bamias A., Manios E. et al.: 24-hour arterial blood pressure monitoring in patients with renal cell carcinoma treated with sunitinib results in control of hypertension without dose reduction in the majority of patients. Ann. Oncol. 2008; 18(suppl; abstr 603P): 195.
36. Houk B.E., Bello C.L., Michaelson M.D., Bukowski R.M., Redman B.G., Hudes G.R. et al.: Exposure-response of sunitinib in metastatic renal carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J. Clin. Oncol. 2007; 25(suppl 18): 241s.
37. Rini B.I.: Biomarkers: hypertension following anti-angiogenesis therapy. Clin. Adv. Hematol. Oncol. 2010; 8(6): 415-6.
38. Rini B.I., Cohen D.P., Lu D., Chen I., Hariharan S., Gore M.E.: Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. ASCO GU meeting 2010; Abstr 312.
39. Ravaud A., Sire M.: Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and secondline treatment of metastatic renal cell cancer. Ann. Oncol. 2009; 20: 966-967.
40. Rixe O., Billemont B., Izzedine H.: Hypertension as a predictive factor of sunitinib activity. Ann. Oncol. 2007; 18: 1117.
41. Bono P., Rautiola J., Utriainen T., Joensuu H.: Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011; 50(4): 569-73.
42. Rini B.I., Cohen D.P., Lu D.R., Chen I., Hariharan S., Gore M.E., Figlin R.A., Baum M.S., Motzer R.J.: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2011 May 4; 103(9): 763-73.
43. Szmit S., Langiewicz P., Żołnierek J., Nurzyński P., Zaborowska M., Filipiak K.J., Opolski G., Szczylik C.: Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines. Kidney Blood Press Res. 2011 Aug 18; 35(1): 18-25.
44. Ghoreschi K., Laurence A., O’Shea J.J.: Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 2009; 10: 356-360.
45. Kerkela R., Woulfe K.C., Durand J.B. et al.: Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2009; 2: 15-25.
46. Hsieh P.C., MacGillvray C., Gannon J., Cruz F.U., Lee R.T.: Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114: 637-44.
47. Khakoo A.Y.: Regulation of hypertrophic responses by PDGFRβ. American Heart Association, Basic Cardiovascular Sciences annual meeting. Lake Las Vegas, NV; 2009 July 21st.
48. Wang C.H., Anderson N., Li S.H. et al.: Stem cell factor deficiency is vasculoprotective: Unraveling a new therapeutic potential of imatinib mesylate. Circ. Res. 2006; 99: 617-625.
49. Steinberg S.F.: PI3King the L-type calcium channel activation mechanism. Circ. Res. 2001; 89: 641-644.
50. Di Lorenzo G., Autorino R., Bruni G. et al.: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol. 2009; 20(9): 1535-1542.
51. Bamias A., Lainakis G., Manios E., Koroboki E., Karadimou A., Zakopoulos N., Dimopoulos M.A.: Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J. Clin. Oncol. 2009 May 20; 27(15): 2567-9.
52. Khakoo A.Y., Kassiotis C.M., Tannir N., Plana J.C., Halushka M., Bickford C. et al.: Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-8.
53. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S.: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 2008; 19: 1613-8.
54. Szmit S., Nurzyński P., Szaluś N., Opolski G., Szczylik C.: Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2009; 48(6): 921-5.
55. Schmidinger M., Zielinski C.C., Vogl U.M. et al.: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008; 26: 5204-5212.
56. Jain M., Townsend R.R.: Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr. Hypertens. Rep. 2007; 9(4): 320-328.
57. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G.: Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Cancer Urol. Assoc. J. 2007; 1(Suppl): S41-S54.
58. Lacy C.F., Armstrong L.L., Goldman M.P.: Cytochrome P-450 enzymes and drug metabolism. W: Drug information handbook. Lacy C.F., Armstrong L.L., Goldman M.P (red.). Wyd. 12. Hudson, Ohio: Lexi-Comp; 2004: 1619-1631.
59. Szmit S., Filipiak K.J.: Nadciśnienie jako powikłanie współczesnej farmakoterapii onkologicznej. W: Nadciśnienie tętnicze – co nowego? Kasprzak J.D., Nowicki M. (red.). Cornetis (w druku).
60. Dougall H.T., McLay J.: A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996; 15: 91-106.